Media stories about Catabasis Pharmaceuticals (NASDAQ:CATB) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.9590705515254 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

A number of research firms recently weighed in on CATB. Zacks Investment Research lowered shares of Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Citigroup set a $3.50 price target on shares of Catabasis Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, October 5th. CIBC reaffirmed an “outperform” rating and set a $7.00 price target (up from $4.00) on shares of Catabasis Pharmaceuticals in a report on Thursday, October 5th. Finally, Oppenheimer raised their price target on shares of Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an “outperform” rating in a report on Thursday, October 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $4.82.

Catabasis Pharmaceuticals (CATB) remained flat at $$1.53 on Friday. 104,065 shares of the company’s stock were exchanged, compared to its average volume of 212,751. Catabasis Pharmaceuticals has a 12-month low of $1.08 and a 12-month high of $5.00. The firm has a market capitalization of $35.32 and a price-to-earnings ratio of -1.01.

Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02. The company had revenue of $0.25 million for the quarter. sell-side analysts expect that Catabasis Pharmaceuticals will post -1.38 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-catabasis-pharmaceuticals-catb-stock-price/1814270.html.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Insider Buying and Selling by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.